SALUTENSIN
LOE ApproachingNDAORALTABLET
Approved
Jun 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SALUTENSIN is an oral tablet product approved by Takeda in 1960 with an unknown mechanism of action and indication profile. The specific therapeutic indication cannot be determined from available data.
LOE Approaching
With LOE approaching and competitive pressure rated at 30%, this product is in decline phase, likely with minimal expansion of commercial team resources.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and approaching LOE indicate this is a declining asset with minimal hiring. Professionals on this team should prepare for portfolio transition or career movement to growth-stage products.
Brand ManagerField Sales
Worked on SALUTENSIN at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.